Skip to main content
69°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xeris Biopharma Holdings, Inc. - Common Stock
(NQ:
XERS
)
4.325
-0.325 (-6.99%)
Streaming Delayed Price
Updated: 10:52 AM EDT, Jun 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xeris Biopharma Holdings, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
June 03, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Details for Analyst & Investor Day
May 20, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
May 08, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
May 06, 2024
Via
ACCESSWIRE
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
May 01, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
April 17, 2025
From
Bright Peak Therapeutics, Inc.
Via
GlobeNewswire
Xeris Announces Changes to Its Board of Directors
March 28, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
March 17, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
March 06, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025
February 27, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
February 24, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in Upcoming Investor Conferences
February 05, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
January 10, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 06, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
Xeris Biopharma
Via
Business Wire
Xeris Biopharma Reports Third Quarter 2024 Financial Results
November 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
October 31, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 04, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in Upcoming Investor Conferences
August 22, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces CEO Succession Plan
July 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
June 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
May 30, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
May 09, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
May 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
